Mohammed Shameem

Dr. Mohammed Shameem, currently Vice President and Head of Drug Product and New Technology Development at Regeneron Pharmaceuticals, USA, is a dedicated pharmaceutical scientist who has been involved in the development and commercialization of innovative, lifesaving biologics and small molecules for over 25 years. After earning his B. Pharm and M. Pharm degree in Pharmacy from University of Dhaka, Bangladesh, Dr. Shameem received a PhD in Pharmaceutical Sciences from Kumamoto University, Japan. He received additional postdoctoral training at National Institute of Health Sciences (NIHS), Japan, University of Southern California and University of Kentucky before joining the industry.

His recent noteworthy accomplishments include leading the drug product development of Regeneron’s COVID-19 monoclonal antibody cocktail (REGEN-COV™ or Ronapreve™) for the treatment and prevention of SARS CoV-2. In addition, Dr. Shameem played a leading role in the development of three monoclonal antibody cocktail product, INMAZEB™, for the treatment of Ebola. Prior to joining Regeneron Pharmaceuticals, Dr. Shameem held the position of Executive Director in the Bioprocess Development of Merck, where he played a key role in the development of monoclonal antibody products. Most notably, he led the CMC development effort for the anti-PD1 immune checkpoint inhibitor, KETRUDA, which is a breakthrough immune-oncology product in the treatment of cancer as monotherapy or combination therapy.

Dr. Shameem has received several industrial awards; Heroes of Chemistry Award in 2021 for Innovation in Medicine and Industrial Biotechnology Award in 2016 for distinguished industrial accomplishments on biotechnology given by American Chemical Society (ACS). He has to his credit numerous international publications, book chapters, and he has edited several books in his areas of expertise.